Brain

The following list provides a brief description of brain cancer trials that are open for recruitment in Western Australia. If you would like more information please follow the links provided, contact one of the trial sites or speak with your doctor.

Please note that this list is based on information provided to the Cancer Council by WA hospitals and may not include all clinical trials that are running in WA.

Where ‘N/A' appears - this means the lacking information has not been provided to date to the Cancer Council.

F.I.G

Registered Title	A prospective, multicentre trial evaluating the use of O-(2-[18F]-fluoroethyl)-L-tyrosine Positron Emission Tomography (FET-PET) imaging in radiotherapy planning and clinical management of people with glioblastoma.
Purpose	To investigate how the addition of FET-PET imaging to standard MRI imaging affects radiation target volume delineation and treatment planning for GBM. To determine the accuracy and management impact of FET-PET in distinguishing pseudoprogression from true tumour progression and / or tumour recurrence.
Lay Summary	It is hoped that this new imaging approach with FET-PET scans will lead to more accurate assessment, and improve both treatment decisions and outcomes for patients with Glioblastoma. Currently FET-PET scans are not part of routine care for patients diagnosed with Gliobastoma. The use of FET-PET is experimental.
WA Trial Sites	Radiation Oncology  Ph. (08) 6383 3204
Links	Australia New Zealand Clinical Trials Registry

Acknowledgements: Australia New Zealand Clinical Trials Registry

MoST 6

Registered Title	Single arm, open label, signal seeking, phase IIa trial of the activity of larotrectinib in patients with advanced NTRK1-3 positive tumours
Purpose	The aim of MoST substudies 14 - 15 is to assess the clinical activity of larotrectinib in patients with advanced (rare) solid cancers harbouring NTRK 1-3 rearrangements/fusions into two groups: Group 1: primary central nervous system (CNS) cancers Group 2: non-CNS cancers. Primary and secondary objectives are per framework with one substudy specific objective below. Secondary objectives Progression free survival at 6 months. Tertiary objectives 1. To evaluate biomarkers that may correlate with clinical activity including response, resistance and tolerability 2. To determine the frequency of NTRK1-3 mutations in a population of advanced, adult-onset rare cancers 3. To determine the mechanism of resistance in patients who progress on larotrectinib
Lay Summary	N/A
WA Trial SItes	Ph. 08 6382 5513
Links	Australia New Zealand Clinical Trials Registry

Acknowledgements: Australia New Zealand Clinical Trials Registry

MAGMA

Registered Title	A multi-arm multi-stage, multi-centre, phase III (MAMS) platform trial that aims to assess hypotheses against a common standard-of-care control arm for the management of people with glioblastoma.
Purpose	"This study aims to evaluate the use of temozolomide in different regimes for Glioblastoma. The trial is testing two changes to the usual schedule of treatment.
Lay Summary	It is hoped this research will help identify if starting temozolomide earlier than usual and/or continuing treatment with temozolomide for longer than usual will improve the outcomes of people with glioblastoma and assist development of future treatments."
WA Trial Sites	Medical Oncology Ph. (08) 6383 3000
Links	Australia New Zealand Clinical Trials Registry

Acknowledgements: Australia New Zealand Clinical Trials Registry

EX-TEM

Acknowledgements: Australia New Zealand Clinical Trials Registry

OUTRUN / TROG 17.02

Acknowledgements: US National Library of Medicine

[Return to List of Clinical Trials]